A recently developed bifunctional antibody named GPC3-targeted TRAB (T cell-redirecting antibody) has shown immunotherapeutic promise even in non-HCC cancers that express low but distinct levels of GPC3 and is currently in phase I trial. Here, GPC3 is linked to cancer.